Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Snurportin-1 (SNUPN) is a 360-amino acid nuclear import adaptor protein encoded by the SNUPN gene on human chromosome 15. It binds the trimethylguanosine (m3G) cap found on spliceosomal U snRNPs and interacts with Importin-β1 to mediate snRNP transport into the nucleus, a process essential for proper spliceosome assembly and mRNA processing. The protein has an Importin-β binding domain (IBB) at the N-terminus and a m3G-cap binding region at the C-terminus. Deficiency or mutation in SNUPN leads to defective spliceosomal maturation, cytoskeletal disorganization, and Mendelian recessive muscular dystrophy (LGMDR29), with associated neurological phenotypes. Snurportin-1 is not a drug target or receptor but is essential for normal nuclear transport and gene expression regulation in muscle and neuronal tissues. No interacting drugs or safety concerns are described, and while disease-causing mutations exist, its role as a marker is limited to rare inherited disease diagnosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Snurportin-1 (SNUPN).